Allena Pharmaceuticals, Inc. (ALNA) [Rocket]

In millions, except per share items	Dec-31-21	Dec-31-20	Dec-31-19	Dec-31-18	Dec-31-17	Dec-31-16	Dec-31-15
	10-K	10-K	10-K	10-K	10-K	10-K	10-K
Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of goods sold	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Selling, general and administrative [+]	47.6	32.0	47.5	9.2	5.4	4.1	2.4
General and administrative				9.2	5.4	4.1	2.4
Research and development				26.4	15.5	20.1	11.5
Other operating expenses	2.0	1.7	-0.4	1.2	0.9	0.4	0.7
EBITDA [+]				-36.7	-21.8	-24.5	-14.5
EBITDA growth	47.4%	-28.5%	28.3%	68.9%	-11.3%	69.5%
Depreciation and amortization				0.1	0.1	0.0	0.1
EBIT [+]	-49.7	-33.7	-47.2	-36.8	-21.8	-24.6	-14.6
EBIT growth	47.4%	-28.5%	28.0%	68.7%	-11.2%	68.7%
Interest income	-1.0	-0.5	0.3	0.6	0.4	0.2	0.3
Interest income	-1.0	-0.5	0.3	0.6	0.4	0.2	0.3
Other income (expense), net [+]	2.0	1.4	-0.5	0.6	-0.3	-0.1	0.0
Gain (loss) on debt retirement				-0.6
Other				0.0	-0.3	-0.1	0.0
Pre-tax income	-48.7	-32.8	-47.3	-35.6	-21.7	-24.5	-14.2
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-48.7	-32.8	-47.3	-35.6	-21.7	-24.5	-14.2

Basic EPS [+]	($0.72)	($1.01)	($2.13)	($1.72)	($4.79)	($18.30)	($11.32)
Growth	-29.1%	-52.7%	24.2%	-64.1%	-73.8%	61.6%
Diluted EPS [+]	($0.72)	($1.01)	($2.13)	($1.72)	($4.79)	($18.30)	($11.32)
Growth	-29.1%	-52.7%	24.2%	-64.1%	-73.8%	61.6%

Shares outstanding (basic) [+]	68.0	32.5	22.2	20.7	4.5	1.3	1.3
Growth	109.1%	46.6%	6.9%	358.8%	237.5%	6.4%
Shares outstanding (diluted) [+]	68.0	32.5	22.2	20.7	4.5	1.3	1.3
Growth	109.1%	46.6%	6.9%	358.8%	237.5%	6.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.